rtainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
PERRIGO COMPANYCONDENSED CONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share amounts)(unaudited)Three Months EndedSix Months EndedDecember 29, 2012December 31, 2011December 29, 2012December 31, 2011Net sales
$
882,959$
838,170$
,652,769$
,563,465Cost of sales
575,794543,2951,060,3351,041,011Gross profit
307,165294,875592,434522,454Operating expenses Distribution
11,6999,09522,46619,359 Research and development
28,32331,14855,71850,786 Selling and administration
103,28693,964193,820190,089 Total operating expenses
143,308134,207272,004260,234Operating income
163,857160,668320,430262,220Interest, net
15,31415,64131,16728,211Other expense, net
7675214981Loss on sale of investment
3,049—3,049—Income before income taxes
145,418144,275286,200233,028Income tax expense
39,46344,53674,66562,831Net income
$
5,955$
99,739$
211,535$
70,197Earnings per shareBasic earnings per share
$
.13$
.07$
2.26$
.83Diluted earnings per share
$
.12$
.06$
2.24$
.81Weighted average shares o
'/>"/>
SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Related medicine technology :1.
Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million2.
Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%3.
Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 20134.
Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx5.
Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%6.
Perrigo Company To Present At The Credit Suisse Healthcare Conference7.
Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance8.
Perrigo Company Announces Appointment Of New Board Of Directors Member9.
Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million10.
Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference11.
Perrigo Company Announces Quarterly Dividend